Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fluid volume regulation in patients with heart failure - Authors' reply

    Research output: Contribution to journalLetterResearchpeer-review

  2. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. BPA and risk assessment

    Research output: Contribution to journalLetterResearchpeer-review

  1. Coagulation parameters in the newborn and infant - the Copenhagen Baby Heart and COMPARE studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lipoprotein(a) levels at birth and in early childhood: The COMPARE Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Left ventricular thrombus in multisystem inflammatory syndrome in children associated with COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: No medical treatment has been reliably shown to halt or reverse disease progression in hypertrophic cardiomyopathy, but the results of several pilot studies have suggested beneficial effects of angiotensin II receptor blockers on left ventricular hypertrophy and fibrosis, which are predictive of an adverse outcome. We aimed to assess the effect of the angiotensin II receptor blocker losartan on left ventricular hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.

METHODS: In this single-centre, randomised, double-blind, placebo-controlled trial, adult patients (aged 18 years and older) with obstructive or non-obstructive hypertrophic cardiomyopathy were randomly assigned via computer-based system to losartan (100 mg per day) or placebo for 12 months. Patients and investigators were masked to assigned treatment. The primary endpoint was change in left ventricular mass as assessed by cardiac magnetic resonance imaging (CMR) or CT. Efficacy analyses were done in the modified intention-to-treat population (all patients with data available at the 12-month follow-up). The trial is registered with ClinicalTrials.gov, number NCT01447654.

FINDINGS: Between Dec 1, 2011, and May 1, 2013, 318 patients were screened. 133 patients (mean age 52 years [SD 13], 35% women) consented and were randomly assigned to placebo (n=69) or losartan (n=64). 124 (93%) patients completed the study and were included in the modified intention-to-treat analysis for the primary endpoint. After 12 months we noted no significant difference in the change in left ventricular mass between the placebo group and the losartan group (mean difference 1 g/m(2), 95% CI -3 to 6; p=0·60). A decrease in systolic blood pressure in the losartan group (from mean 127 mm Hg [SD 12] to 121 mm Hg [14]; p=0·0001) confirmed drug compliance; blood pressure did not decrease in the placebo group. Two (2%) patients, both in the placebo group, died from sudden cardiac death during follow-up. In the losartan group, one (1%) patient had angioedema, one (1%) had deterioration of renal function, and one (1%) had hyperkalaemia. Treatment was well tolerated by patients with left ventricular outflow obstruction at baseline.

INTERPRETATION: Our findings challenge the generally held view that angiotensin II receptor blockers reduce cardiac hypertrophy. Treatment with losartan was safe, suggesting that it can be used for other indications in patients with hypertrophic cardiomyopathy, irrespective of obstructive physiology. Additional studies are needed to assess the effect of angiotensin II receptor blockers in preclinical hypertrophic cardiomyopathy-eg, in genotype-positive but phenotype-negative individuals.

Original languageEnglish
JournalThe Lancet, Diabetes & Endocrinology
Volume3
Issue number2
Pages (from-to)123-31
Number of pages9
ISSN2213-8587
DOIs
Publication statusPublished - Feb 2015

    Research areas

  • Angiotensin II Type 1 Receptor Blockers, Cardiomyopathy, Hypertrophic, Double-Blind Method, Female, Fibrosis, Follow-Up Studies, Heart Ventricles, Humans, Hypertrophy, Left Ventricular, Losartan, Male, Middle Aged, Treatment Outcome

ID: 46172692